Taysha Gene Therapies (TSHA) just unveiled an announcement.
Taysha Gene Therapies, Inc. has shared upbeat clinical results from their REVEAL Phase 1/2 trials, which show promise in treating Rett Syndrome with their TSHA-102 therapy in both adult and pediatric patients. The announcement, which could stir investor interest, was made through a press release and is supported by a detailed presentation available on the company’s website. These findings, while preliminary, have not been filed with regulatory authorities but serve as a positive indicator of the therapy’s potential impact.
For detailed information about TSHA stock, go to TipRanks’ Stock Analysis page.
